⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3053425 | 1.00 | — | — | |
| SCHEMBL18099886 | 0.73 | — | — | |
| SCHEMBL11830244 | 0.71 | — | — | |
| SCHEMBL11830252 | 0.71 | — | — | |
| SCHEMBL28903995 | 0.67 | — | — | |
| SCHEMBL13547369 | 0.65 | — | — | |
| SCHEMBL3585830 | 0.65 | — | — | |
| SCHEMBL14781545 | 0.65 | — | — | |
| SCHEMBL3585828 | 0.65 | — | — | |
| SCHEMBL3253097 | 0.65 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4306166-A2 | COMPOUNDS, COMPOSITIONS AND METHODS OF USE | Aquinnah Pharmaceuticals Inc. (US) | 2024-01-17 | — | — | EP | disclosed |
| US-11827638-B2 | Imidazopyrrolopyridine as inhibitors of the JAK family of kinases | JANSSEN PHARMACEUTICA NV (BE) | 2023-11-28 | — | — | US | disclosed |
| US-20230303489-A1 | COMPOUNDS, COMPOSITIONS AND METHODS OF USE | AQUINNAH PHARMACEUTICALS INC (US) | 2023-09-28 | — | — | US | disclosed |
| EP-3557998-B1 | COMPOUNS, COMPOSITIONS AND METHODS OF USE | AQUINNAH PHARMACEUTICALS INC (US) | 2023-08-16 | — | — | EP | disclosed |
| US-11542233-B2 | Compounds, compositions and methods of use | AQUINNAH PHARMACEUTICALS, INC. (US) | 2023-01-03 | — | — | US | disclosed |
| EP-3555096-B1 | IMIDAZOPYRROLOPYRIDINE AS INHIBITORS OF THE JAK FAMILY OF KINASES | JANSSEN PHARMACEUTICA NV (BE) | 2022-11-23 | — | — | EP | disclosed |
| CN-114685505-A | Imidazopyrrolopyridines as JAK family kinase inhibitors | 詹森药业有限公司 | 2022-07-01 | — | — | CN | disclosed |
| CN-110312719-B | Imidazopyrrolopyridines as JAK family kinase inhibitors | 詹森药业有限公司 | 2022-04-15 | — | — | CN | disclosed |
| US-20210206768-A1 | IMIDAZOPYRROLOPYRIDINE AS INHIBITORS OF THE JAK FAMILY OF KINASES | JANSSEN PHARMACEUTICA NV (BE) | 2021-07-08 | — | — | US | disclosed |
| WO-2021121327-A1 | SUBSTITUTED STRAIGHT CHAIN SPIRO DERIVATIVES | JANSSEN PHARMACEUTICA NV (BE) | 2021-06-24 | — | — | WO | disclosed |
| US-20120095011-A1 | NOVEL COMPOUNDS | ASTRAZENECA AB (SE) | 2012-04-19 | — | — | US | disclosed |
| US-20100190687-A1 | PYRIMIDINONE DERIVATIVES AND METHODS OF USE THEREOF | SCHERING CORPORATION | 2010-07-29 | — | — | US | disclosed |
| EP-2148869-A1 | PYRIMIDINONE DERIVATIVES AND METHODS OF USE THEREOF | SCHERING CORPORATION (US) | 2010-02-03 | — | — | EP | disclosed |
| US-20090131463-A1 | NOVEL COMPOUNDS | ASTRAZENECA AB (SE) | 2009-05-21 | — | — | US | disclosed |
| US-7521453-B2 | e.g. 5-Bromo-2-(3-methylisoxazol-5-ylmethylamino)-4-(5-cyclopropyl- 1H-pyrazol-3-ylamino)pyrimidine; anticarcinogenic, antitumor agents; breast, prostate, colon cancer | ASTRAZENECA AB (SE) | 2009-04-21 | — | — | US | disclosed |
| EP-1456182-B1 | PYRIMIDINE DERIVATIVES AS MODULATORS OF INSULINE-LIKE GROWTH FACTOR-1 RECEPTOR (IGF-I) | ASTRAZENECA AB (SE) | 2009-03-11 | — | — | EP | disclosed |
| WO-2008130581-A1 | PYRIMIDINONE DERIVATIVES AND METHODS OF USE THEREOF | SCHERING CORPORATION (US) | 2008-10-30 | — | — | WO | disclosed |
| CN-1289486-C | Pyrimidine derivatives as modulators of insulin-like growth factor-1 receptor (igf-1) | ASTRAZENECA AB (SE) | 2006-12-13 | — | — | CN | disclosed |
| CN-1617858-A | Pyrimidine derivatives as modulators of insulin-like growth factor-1 receptor (igf-1) | ASTRAZENECA AB (SE) | 2005-05-18 | — | — | CN | disclosed |
| US-20050054638-A1 | Pyrimidine derivatives as modulators of insulin-like growth factor-1 receptor (igf-i) | ASTRAZENECA AB | 2005-03-10 | — | — | US | disclosed |